Daiichi pays $225m to access gene therapy production platform

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Katy L. Pack)
(Image: Getty/Katy L. Pack)

Related tags: Daiichi sankyo, Ultragenyx, Gene therapy, AAV platform

Daiichi partners with Ultragenyx to utilize its HeLa producer cell line platform for commercial-scale gene therapy production.

In return for access to the adeno-associated virus (AAV) platform, Daiichi Sankyo was prepared to offer $200m (€185m) upfront to Ultragenyx.

The platform at the center of the deal is HeLa, a producer cell line platform that allows for the large commercial-scale production of gene therapies. Ultragenyx states that this platform is ‘more consistent’ and ‘less expensive’ in comparison to other gene therapy manufacturing platforms.

Also included in the deal is Ultragenyx’s proprietary HEK293 transient transfection system for AAV manufacture.

Daiichi will receive non-exclusive access to the technology for use in its internal gene therapy projects.

Once technology transfer is completed to Daiichi, the company will then pay an additional $25m. Ultragenyx will receive single-digit royalties on net sales of any Daiichi product manufactured by the technology.

Masayuki Yabuta, head of Daiichi Sankyo’s biologics division, said, “In order to provide these drugs to patients in the future, manufacturing technology must be established early. Ultragenyx's proprietary technology is particularly excellent in terms of stable quality, high production efficiency, and ability to accommodate mass production.”

According to Daiichi, the company is interested in the development of gene therapies for retinal diseases and rare diseases, as well as specifying​ that it has no interest in gene therapy to insert genetic material into the host genome.

Yabuta added that the company is currently doing discovery research in the gene therapy area, which Daiichi sees as offering long-term business potential once it completes its strategic plan moving toward 2025, marked by a shift towards the development and licensing of oncology-focused assets.

The agreement Ultragenyx has signed with Daiichi features the option for the former company to co-develop and co-commercialize any rare disease product at the investigational new drug stage.

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us


View more